TL;DR
This meta-analysis of over 4.4 million participants provides robust evidence that maternal hypertension, particularly gestational hypertension and preeclampsia, significantly increases the risk of cleft lip and palate (CLP) in offspring. While the association is clear, the authors emphasize that residual confounding means causality cannot be definitively established, calling for more high-quality prospective studies.
What Problem Does This Paper Address?
Cleft lip and palate (CLP) is a common congenital anomaly with significant impacts on individuals and society. While many risk factors are known (e.g., genetics, smoking, diabetes), the role of maternal hypertension has been less clear, with existing studies showing inconsistent results and significant heterogeneity. This inconsistency makes it difficult for clinicians to provide accurate risk assessments and for researchers to understand the underlying biological mechanisms. This paper aims to synthesize the available evidence to provide a clearer picture of the association between maternal hypertension and CLP risk.
Methods
The researchers conducted a systematic review and meta-analysis, adhering to MOOSE guidelines. They systematically searched major electronic databases (PubMed, Cochrane Library, Embase, Web of Science) for observational studies investigating the link between maternal hypertension and CLP. Data extraction and risk-of-bias assessments were performed independently by two researchers. A meta-analysis was conducted using Stata 18.0 and Revman 5.3, employing random-effects models to account for heterogeneity. They also performed sensitivity analyses to assess the robustness of their findings and subgroup analyses to explore variations based on study design, quality, and specific hypertensive phenotypes (gestational hypertension, preeclampsia, pre-pregnancy hypertension).
Datasets
The study did not introduce new datasets. Instead, it synthesized data from 12 previously published observational studies. These studies included a mix of cohort, case-control, and cross-sectional designs, contributing a total of 4,407,254 participants.
Key Insights and Ideas
- Stronger Association Than Previously Thought: The meta-analysis reveals a statistically significant association between maternal hypertension and CLP risk, with an overall odds ratio of 1.44. This suggests that hypertension is a more substantial risk factor than some previous reviews might have indicated.
- Specific Hypertensive Conditions Matter: The study highlights that both gestational hypertension (OR=1.36) and preeclampsia (OR=2.10) are independently associated with an increased risk of CLP, with preeclampsia showing a particularly strong link.
- Robustness Despite Heterogeneity: While significant heterogeneity was observed (I²=55%), sensitivity analyses confirmed that the overall findings were robust and not driven by any single study. This suggests the association is consistent across different research contexts.
- Confounding is a Persistent Challenge: The authors repeatedly emphasize that while they attempted to control for major confounders (maternal age, diabetes, smoking, BMI, etc.), residual confounding is a significant limitation. This means the observed association might be partly explained by unmeasured factors.
- Mechanisms Remain Speculative: The paper discusses potential biological pathways (e.g., placental hypoxia, oxidative stress, impact on neural crest cell development) but stresses these are hypotheses extrapolated from other research and not directly proven by this meta-analysis.
Key Results
- Overall Association: Maternal hypertension was associated with a 44% increased risk of CLP in offspring (OR = 1.44, 95% CI = 1.26-1.64, p = 0.01).
- Gestational Hypertension: Associated with a 36% increased risk (OR = 1.36, 95% CI = 1.06-1.74, p = 0.01).
- Preeclampsia: Associated with a 110% increased risk (OR = 2.10, 95% CI = 1.11-3.96, p = 0.02).
- Heterogeneity: Overall heterogeneity was moderate (I²=55%, p=0.01), but varied across subgroups.
- Subgroup Analyses: The association persisted across different study designs (cohort, case-control), quality levels (high/moderate), and when adjusting for major confounders, though effect sizes were modestly attenuated.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Nature: Many included studies were retrospective, potentially leading to recall bias.
- Residual Confounding: The intricate interplay of factors like socioeconomic status, nutritional status, and the severity/duration of hypertension means that unmeasured confounders could still influence the results.
- Inconsistent Definitions: Variations in how hypertension was defined across studies contributed to heterogeneity.
- Language Bias: Only English-language articles were included.
- Medication vs. Disease: It's challenging to disentangle the effects of the hypertensive disease state from the effects of antihypertensive medications, as treatment is often linked to disease severity.
Future work should focus on:
- High-Quality Prospective Cohorts: These are needed to establish causality, precisely measure exposure timing, and control for a wider range of confounders.
- Harmonized Definitions: Standardized definitions for hypertension and exposure assessment are crucial.
- Investigating Antihypertensive Drugs: Further research is needed to clarify the specific risks associated with different classes of antihypertensive medications.
- Exploring Biological Mechanisms: More studies are required to validate the proposed biological pathways linking maternal hypertension to CLP.
Summary updated